Drugs / NPO-13
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02265939 Comparator | Oct 2014 → Mar 2015 | intestinal disorder | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPO-13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02265939 ↗ |
| Route | Other | “receive an intraluminal spraying of NPO-13 per contraction region of large bowel” NCT02265939 ↗ |